secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2026-07-30T11:05:16+00:00
Accession:  0001193125-26-324866
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint completes enrollment in both Phase 3 DME trials of DURAVYU; topline data Q4 2027
--------------------------------------------------------------------------------

- Over 480 patients enrolled across COMO and CAPRI trials in five months, ahead of schedule.
- Topline 56-week data for both DME trials anticipated in Q4 2027.
- DSMC reviewed masked safety data in May 2026 and recommended continuation of both programs.
- DURAVYU evaluated in over 190 patients across four completed trials with favorable safety profile.
- Phase 3 program developed in alignment with FDA and EMA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000119312526324866/0001193125-26-324866-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000119312526324866/eypt-20260730.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-324866

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer